Trial Profile
A Randomized, Open-Label, Parallel-Group Study to Evaluate the Safety and Efficacy of Two Dosing Regimens of Netarsudil Ophthalmic Solution in Patients With Corneal Edema Due to Fuchs Corneal Dystrophy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Dec 2022
Price :
$35
*
At a glance
- Drugs Netarsudil (Primary)
- Indications Fuchs' endothelial dystrophy
- Focus Therapeutic Use
- Sponsors Aerie Pharmaceuticals
- 01 Dec 2022 Primary endpoint (Central Corneal Thickness (CCT)) has been met, according to results published in the Journal of Ocular Pharmacology and Therapeutics.
- 01 Dec 2022 Results published in the Journal of Ocular Pharmacology and Therapeutics
- 20 Apr 2022 According to an Aerie Pharmaceuticals media release, data will be presented at the American Society of Cataract and Refractive Surgery (ASCRS 2022).